Clinical Drug Investigation

, Volume 27, Issue 5, pp 347–355 | Cite as

Impact of Losartan on Stroke Risk in Hypertensive Patients in Primary Care

  • K. Bestehorn
  • Klaus Wahle
Original Research Article


Background and objective: While a number of conditions and risk factors that increase stroke risk have been identified, arterial hypertension is the most consistent and powerful predictor. The angiotensin II type 1 receptor antagonist (angiotensin receptor blocker [ARB]) losartan has been shown in the LIFE (Losartan Intervention for Endpoint Reduction in Hypertension) study to decrease stroke risk in hypertensive patients to a substantially greater extent than conventional therapy. We aimed to assess the impact of the blood pressure-lowering effect of losartan therapy on stroke risk in hypertensive patients in primary care.

Methods: A total of 2977 primary-care practices throughout Germany included 22 499 consecutive unselected patients with a confirmed diagnosis of hypertension in an open-label, prospective, observational study. In addition to demographics, known risk factors for stroke were documented on standardised questionnaires. The 10-year predicted risk of first stroke was calculated according to the Framingham Stroke Risk Score at baseline and after a mean of 94 ± 24 days of losartan (± hydrochlorothiazide [HCTZ]) therapy.

Results: The mean patient age was 64.1 ± 10.6 years, and 52.4% were males. Mean systolic/diastolic blood pressure decreased from 160 ± 15/93 ± 9mm Hg at baseline by −21 ± 14/−11 ± 9mm Hg. Besides hypertension, 84.9% of patients had other co-morbidities, of which the most frequent were hypercholesterolaemia (53.0%), diabetes mellitus (36.1%), coronary heart disease (31.1%) and left ventricular hypertrophy (24.2%). The average predicted 10-year stroke risk was 28.0 ± 21.9% at baseline, and 22.1 ± 19.5% at study end (relative risk reduction 24 ± 16%, p < 0.05). In subgroups of patients with diabetes or nephropathy, similar effects were noted. Drug-related adverse events were reported in 18 patients; all of these were non-serious.

Conclusion: Because of the high prevalence of co-morbidities and risk factors, the hypertensive patient population observed in this study presented with a high 10-year stroke risk. Treatment with losartan (± HCTZ) was well tolerated and led to a substantial decrease in blood pressure and associated stroke risk.


Losartan Stroke Risk HCTZ Calcium Channel Antagonist Total Cohort 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This study was presented at the Fifteenth European Hypertension Meeting on Hypertension in Milan, Italy, on 17 June 2005. The study was supported by an unrestricted educational grant from MSD Sharp & Dohme GmbH and Chibropharm GmbH, Haar/Munich, Germany.

Dr Bestehorn is an employee of MSD, and is also affiliated with the Medical Faculty of the Technical University of Dresden, Germany. Dr Wahle has no conflicts of interest that are directly relevant to the content of this study. The authors acknowledge the input of D. Pittrow, MD, PhD, Dresden/Munich, to the interpretation of the study.


  1. 1.
    Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997; 349(9064): 1498–504PubMedCrossRefGoogle Scholar
  2. 2.
    Goldstein LB, Adams R, Alberts MJ, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke 2006; 37: 1583–633PubMedGoogle Scholar
  3. 3.
    Kjeldsen SE, Julius S, Hedner T, et al. Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials. Blood Press 2001; 10(4): 190–2PubMedCrossRefGoogle Scholar
  4. 4.
    D’Agostino RB, Wolf PA, Belanger AJ, et al. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke 1994; 25(1): 40–3PubMedCrossRefGoogle Scholar
  5. 5.
    Moen MD, Wagstaff AJ. Losartan: a review of its use in stroke risk reduction in patients with hypertension and left ventricular hypertrophy. Drugs 2005; 65(18): 2657–74PubMedCrossRefGoogle Scholar
  6. 6.
    Institut für Praxisforschung (PRAFO) im BDA [online]. Available from: [Accessed 2006 Jul 12]
  7. 7.
    Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359(9311): 995–1003PubMedCrossRefGoogle Scholar
  8. 8.
    Kizer JR, Dahlof B, Kjeldsen SE, et al. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension 2005; 45(1): 46–52PubMedGoogle Scholar
  9. 9.
    Ferrario CM. The role of angiotensin antagonism in stroke prevention in patients with hypertension: focus on losartan. Curr Med Res Opin 2004; 20(11): 1797–804PubMedCrossRefGoogle Scholar
  10. 10.
    Guidelines committee. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53CrossRefGoogle Scholar
  11. 11.
    International Diabetes Federation. Hypertension in people with type 2 diabetes: knowledge-based diabetes-specific guidelines. Diabet Med 2003; 20(12): 972–87CrossRefGoogle Scholar
  12. 12.
    Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J Am Med Ass 2003; 289(19): 2560–71CrossRefGoogle Scholar
  13. 13.
    Hasford J, Mimran A, Simons W. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002; 16(8): 569–75PubMedCrossRefGoogle Scholar
  14. 14.
    Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Brit Med J 2003; 326(7404): 1427–31PubMedCrossRefGoogle Scholar
  15. 15.
    Pittrow D, Kirch W, Bramlage P, et al. Patterns of antihypertensive drug utilization in primary care. Eur J Clin Pharmacol 2004; 60(2): 135–42PubMedCrossRefGoogle Scholar
  16. 16.
    Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342(25): 1887–92PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Medical DepartmentMSD Sharp & Dohme GmbHHaarGermany
  2. 2.Institute for Clinical PharmacologyTechnical University of DresdenDresdenGermany
  3. 3.Institute for Practice Research, German Primary Care Physician Association (BDA)NittendorfGermany

Personalised recommendations